Located in Raleigh, North Carolina on North Carolina State University's Centennial Campus, ImmunoBiosciences, Inc. has proprietary rights to a novel Immune Complex Vaccine (ICV) technology, which is broadly applicable to both human vaccines and animal vaccines. Also referred to as antibody-antigen complex vaccine technology, the technology allows for improved safety and efficacy of viral and bacterial vaccines, thus offering better vaccination strategies.

ImmunoBiosciences, Inc. improves the standard of human and veterinary medical health through the development of these innovative immune complex vaccines and biologics. We focus on identifying industry needs in these fields and applying proprietary scientific knowledge and technology to those needs to be beneficial to society and lucrative to our employees and shareholders.